iuvo Therapeutics is a pharmaceutical company founded in 2017 and headquartered in Düsseldorf. iuvo’s goal is the reliable supply of high-quality cannabis-based medicines to patients within Europe. iuvo is an independent importer, manufacturer, and wholesaler, constantly expanding its supply chain focusing on established GMP- and GDP-compliant partners. The distribution of our products takes places directly to pharmacies as well as through selected pharmaceutical wholesalers.
iuvo develops its pharmaceuticals based on the latest scientific knowledge. In cooperation with experts in cannabis therapy, the company supports doctors and pharmaceutical specialists through recognized scientific training courses.
iuvo Therapeutics is also an active member of the Federal Association of Pharmaceutical Cannabinoid Companies.
Central EU Supply Hub
Imported, qualified & distributed from the heart of Europe
By successfully adhering to the highest quality standards and releasing the product for sale in Germany, iuvo has strategically positioned itself to be able to service the growing EU market.
Companies that have chosen to release products in another EU country have been facing frequent recalls, product adoption issues and regulatory barriers.
Through a partnership with the logistics specialist Med-X-Press GmbH, iuvo ensures access to its pharma- ceuticals in Germany with a 24h distribution network extending to over 20,000 pharmacies.
Beyond German borders iuvo cooperates with domestic groups in France, Poland, UK, Ireland, Italy, Lithuania, and many more as regulatory frameworks change.
Harmonized Regulatory Frameworks Across the EU
The strategic licence and logistic partnerships of iuvo enable distribution across the EU without regulatory challenges.
Highest Level of Pharmaceutical Compliance
Products are imported, qualified and market released for sale in Germany under review of our Qualified Person (QP) & the renowned pharmaceutical agency of North Rhine-Westphalia.
First Mover Advantage as Countries Open
As cannabinoid therapies become an option for more patients across the EU, iuvo will be able to deliver a tested product portfolio to domestic wholesalers, pharmacies and research entities alike.
Diverse Revenue Streams
Focus on high-margin downstream operations
iuvo is a manufacturer independent EU access-hub for cannabinoid medicines. The Company services both the EU pharmaceutical wholesale (B2B) and direct-to-pharmacy (B2C) markets. A diversified product portfolio and an array of ancillary services such as EU-GMP consulting or white label options enable iuvo to take advantage of several revenue streams simultaneously.
iuvo can service over 20,000 pharmacies in Germany with 24h shipments. The Company has successfully established supply relationships with the 15 leading dispensing pharmacies in the country.
iuvo has secured supply agreements with several leading pharmaceutical wholesalers. The Company achieved this by offering high quality products at competitive pricing and white- label options for a preferred list of partners.
EU-GMP Service Partner
Our pharmaceutical IP and strategic licenses enable us to be selective with our supply partnerships and uphold a competitive advantage in the EU. iuvo secure favorable contract conditions including royalty fees or EU-GMP consulting contracts and more.